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The Divergence
Between Clinical
Guidelines and Practice*
Wilbur Y. W. Lew, MD,
Anthony N. DeMaria, MD
San Diego, California
Clinical guidelines are effective vehicles for incorporating
evidence-based medicine into clinical practice. Experts in
the field review the literature, weigh the strength of the
evidence, and develop specific guidelines based on this
evidence. This approach to achieving quality care has been
championed by cardiovascular subspecialty societies for
decades, including the American College of Cardiology
(ACC), American Heart Association (AHA), European
Society of Cardiology, and others. Writing groups distill
and codify a vast amount of information and form recom-
mendations for practice, which often are ultimately dissem-
inated as joint documents representing multiple societies.
Most guidelines are widely accepted and frequently are the
basis of metrics used to evaluate the performance and quality
of clinical care.
See page 35
If guidelines are accepted as carefully considered consen-
sus opinions from experts, it follows that there should be a
high degree of adherence to those recommendations to
improve outcomes. When there is a divergence between
guideline recommendations and clinical practice, this cre-
ates a dissonance that can be troubling and calls for an
adequate explanation.
In this issue of the Journal, Rassi et al. (1) examine the use
of aldosterone antagonist therapy in patients with acute
myocardial infarction (AMI) manifesting moderate to se-
vere heart failure (HF), reduced ejection fraction (EF)
(40%), and no contraindications (hyperkalemia or history
of renal insufficiency). The Class I recommendation (gen-
*Editorials published in the Journal of the American College of Cardiology reflect the
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this paper to disclose.eral agreement that treatment is beneficial, useful, and
effective) to use these agents, based on level of evidence A
(multiple randomized clinical trials) is presented in the 2004
ACC/AHA guidelines for managing ST-segment elevation
myocardial infarction (STEMI) (2) and in the 2007 ACC/
AHA guidelines for managing patients with unstable
angina/non-STEMI (3). Long-term aldosterone receptor
blockade is recommended in unstable angina/NSTEMI
patients without significant renal dysfunction or hyperkale-
mia who are receiving therapeutic doses of an angiotensin-
converting enzyme inhibitor (ACEI), have a left ventricular
EF 40%, and symptomatic HF or diabetes mellitus (3).
imilar Class I recommendations, Level of Evidence: B are
n the 2005 European Society of Cardiology guidelines for
he diagnosis and treatment of chronic HF (4). The evi-
ence supporting these recommendations was based on 2
arge multicenter trials using aldosterone antagonists: epler-
none in the EPHESUS (Eplerenone Post-Acute Myocar-
ial Infarction Heart Failure Efficacy and Survival Study)
5) and spironolactone in the RALES (Randomized Alda-
tone Evaluation Study) (6).
Rasti et al. (1) examine the use of aldosterone receptor
lockers for patients admitted with AMI to 219 hospitals
etween 2006 and 2009 from the Get With the Guidelines–
oronary Artery Disease (GWTG-CAD) registry. They
ound that 11,255 (13.8%) patients fulfilled guideline crite-
ia for aldosterone antagonist therapy, but only 1,023 (9.1%)
f those qualifying received this treatment at the time of
ospital discharge. There was a wide variation in use among
ospitals, with aldosterone antagonists more likely to be
rescribed in larger hospitals. There was only a small
ncrease in the use of therapy between 2006 and 2009 (from
.0% to 13.4%) (1).
The reasons underlying this wide disparity between a
lass IA recommendation and clinical practice are not
nown. However, the possibilities may be related to barriers
o the awareness, acceptance, or implementation of the
uideline. A lack of awareness is unlikely because 90% of
atients received other guideline-recommended therapies
ncluding aspirin, beta-blockers, ACEIs, or angiotensin
eceptor blockers, and lipid-lowering therapy at discharge
1). Widespread adherence to other guidelines for managing
MI is not surprising because hospitals participating in the
WTG-CAD registry have generally already “bought in”
o the concept of evidence-based medicine. This behavior
ay be reinforced by a hospital culture sensitive to adher-
nce to guidelines because they are included in performance
easures used to judge hospitals for accreditation. There
ay be less focus on recommendations that are not included
n performance measures or in standard admission order
ets. Finally, the relatively small number of patients with
MI who qualify for aldosterone antagonist therapy, 13% in
his study, may decrease awareness and application of this
uideline (1).
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to use aldosterone antagonists may be prevalent among
practicing clinicians. The 2005 ACC/AHA chronic heart
failure guidelines, updated in 2009 (7), also include a Class I
indication to use aldosterone antagonist therapy in patients with
moderately severe to severe HF and reduced left ventricular EF,
again with close monitoring for renal function and potassium.
This is based on Class B Level of Evidence. Adherence to this
guideline has been similarly low as that for post-infarction, with
only 32% of patients hospitalized with HF being discharged with
an aldosterone antagonist (8). This demonstrates a general
esistance to using aldosterone antagonists in either the setting
f HF alone or after AMI, even when it is a Class I
ecommendation.
A major concern with aldosterone antagonists is the risk
f hyperkalemia, which is exacerbated by renal dysfunction
nd may be a life-threatening complication. There was a
-fold increase in the prescription of spironolactone to treat
F after the publication of the RALES, which was asso-
iated with 3-fold increases in hospitalizations for hyperka-
emia and in-hospital mortality (9). In a meta-analysis of
andomized clinical trials using aldosterone-blocking agents
spironolactone, eplerenone, or canrenoate) in patients with
eft ventricular dysfunction, the treatment group compared
ith the control group had a higher incidence of hyperka-
emia (5.9% vs. 3.0%) and worsening renal function (8.9%
s. 1.6%) (10). The risk of hyperkalemia increases with
igher dose ACEIs, nonsteroidal anti-inflammatory drugs,
nd cyclo-oxygenase-2 inhibitors. Concerns about interac-
ions between multiple drugs may become both physician
nd patient barriers to acceptance and decrease medical
ompliance. The guidelines specifically caution against these
isks and recommend careful selection of patients and
onitoring to avoid these complications. However, such
ramatic risks, whether encountered in the published liter-
ture or individual experience, can be a marked deterrent for
hysicians to embrace such therapy, especially if their
ssessment is that the benefit is only modest.
If lack of awareness or poor implementation explains the
isconnect between a guideline and clinical practice, then
he potential exists to improve use by increasing the aware-
ess of the indications and benefits of aldosterone blocker
herapy and improving processes to minimize adverse ef-
ects. However, if the explanation involves a lack of accep-
ance by the medical community, there may be a need to
e-evaluate the specific guideline. If the overwhelming
ajority (86%) of practicing physicians choose not to follow
he guidelines regarding aldosterone antagonist therapy in
MI, yet the vast majority (90%) accept other recommen-
ations, the “wisdom of the crowd” of expert clinical
ractitioners may inform experts in the field as to the need
o re-examine the guideline.
It is well recognized that patients enrolled in multicenter
andomized clinical trials are often not representative of
hose encountered in clinical practice (11). It is possible that
he patients enrolled in the RALES and EPHESUS yieldedifferent results from those seen in the practice setting.
uidelines are updated to incorporate the most current
vidence available. The EPHESUS (5) and RALES (6)
ere published in 2003 and 1999, respectively. Since that
ime, focused updates have provided new evidence to
upport the earlier use of beta-blockers, antiplatelet agents,
nticoagulants, and percutaneous coronary interventions.
here have been advances in other areas as well, such as
lectrophysiological approaches to identify the risks of and
o prevent sudden cardiac death. The guidelines recommen-
ation for aldosterone blockers was based largely on the
ecrease in sudden death observed with eplerenone in the
PHESUS (5). As this dynamic and rapidly changing field
volves, the management of current AMI patients may differ
ignificantly from that of patients treated in the EPHESUS
nd RALES. Recommendations need to reflect contempo-
ary medication and management practices, which may
odify (increase or decrease) the benefits derived from
ldosterone antagonist therapy.
The mechanisms of the cardioprotective effects of aldo-
terone antagonists remain to be elucidated. The survival
enefits of eplerenone in HF patients post-MI are unrelated
o either its diuretic or potassium-sparing effects (12). It has
een postulated that these drugs may be protective by
ncreasing intracellular potassium to decrease arrhythmias.
everal drugs have cardioprotective mechanisms other than
heir primary action (e.g., pleiotropic effects of statins). As
ata emerge regarding mechanisms, the guidelines for
ldosterone antagonists may be modified.
In conclusion, clinical guidelines are valuable for applying
ata-based evidence derived from clinical studies to the
irect care of patients. When there is a divergence between
linical practice and recommended guidelines, as exists in
he use of aldosterone antagonists, the causes need to be
dentified. If poor adherence results from a lack of knowl-
dge or means of implementation, corrective measures must
e taken to improve outcomes. However, it must be ac-
epted that failure to follow guidelines by the vast majority
f physicians may indicate that the evidence base is not
redictive of the results that will be obtained in contempo-
ary clinical practice. Recommendations need to be re-
valuated based on how representative trial enrollees are of
ontemporary patients encountered by practicing physi-
ians, newly emerging evidence, changes in context, and a
road view of why some guidelines are not embraced by
hysicians and/or patients. Resolving apparent discrepancies
s fundamental to the processes by which advances in
edicine and science are made.
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